In this study, we aimed to evaluate the potential of utilizing the aberrant PI3Kδ-S (or PIK3CD-S splice variant) as a precision biomarker and to further develop PI3Kδ-S as a novel drug target for PCa and other endocrine/solid tumors. The gene discussed is PIK3CD; the disease is posterior cortical atrophy.